Literature DB >> 22137869

Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells.

Liliana Rockenbach1, Luci Bavaresco, Patrícia Fernandes Farias, Angélica Regina Cappellari, Carlos Henrique Barrios, Fernanda Bueno Morrone, Ana Maria Oliveira Battastini.   

Abstract

Bladder cancer is the most prevalent tumor in the genitourinary tract and the current treatments are not efficient to prevent recurrence and progression of tumor cases. Studies have revealed evidence of the involvement of the purinergic system in bladder tumorigenesis, particularly ecto-5'-NT/CD73, the enzyme responsible for AMP hydrolysis. Quercetin (3,3',4',5,7-pentahydroxyflavone) is a plant-derived flavonoid that has been shown to exert a broad range of pharmacologic properties, including potential anticancer activity. Here, we investigated the quercetin effect on the E-NTPDases and ecto-5'-nucleotidase/CD73, which catalyzes the introversion of the extracellular purine nucleotides in T24 human bladder cancer cells. The results showed that this flavonoid was able to increase ADP hydrolysis and inhibit the ecto-5'-nucleotidase/CD73 activity, with no effect on protein expression. The treatment with APCP (α,β-methyleneadenosine-5'-diphosphate), another ecto-5'-NT/CD73 inhibitor, led to a significant reduction in cell proliferation. In addition, we showed that AMP, which can be accumulating by enzyme inhibition, had an antiproliferative effect on T24 cells, which was enhanced when its hydrolysis was inhibited by APCP treatment. Otherwise, adenosine did not cause any significant effect on cell proliferation and the quercetin effects were not altered by the simultaneous presence of adenosine. Taken together, the results suggest that the antiproliferative effect of quercetin on tumor cells may occur, at least in part, via alterations in the extracellular catabolism of nucleotides, that could be by AMP accumulation, or could be due to blocked adenosine receptors by this flavonoid, supporting the potential use of quercetin in bladder cancer treatment.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; E-NTPDases; Ecto-5′-nucleotidase; Ectonucleotidases; Purinergic signaling; Quercetin

Mesh:

Substances:

Year:  2011        PMID: 22137869     DOI: 10.1016/j.urolonc.2011.10.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  16 in total

1.  Protective effect of quercetin in ecto-enzymes, cholinesterases, and myeloperoxidase activities in the lymphocytes of rats exposed to cadmium.

Authors:  Fátima Husein Abdalla; Andréia Machado Cardoso; Roberta Schmatz; Jamile Fabbrin Gonçalves; Jucimara Baldissarelli; Caroline Curry Martins; Daniela Zanini; Lizielle Souza de Oliveira; Pauline da Costa; Victor Camera Pimentel; Luciane Belmonte Pereira; Cibele Lima Lhamas; Maria Rosa Chitolina Schetinger; Vera Maria Morsch; Cinthia Melazzo Andrade Mazzanti
Journal:  Mol Cell Biochem       Date:  2014-07-27       Impact factor: 3.396

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

3.  NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.

Authors:  Liliana Rockenbach; Elizandra Braganhol; Fabrícia Dietrich; Fabrício Figueiró; Manoella Pugliese; Maria Isabel Albano Edelweiss; Fernanda Bueno Morrone; Jean Sévigny; Ana Maria Oliveira Battastini
Journal:  Purinergic Signal       Date:  2014-01-26       Impact factor: 3.765

Review 4.  Purinergic signalling in the urinary tract in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

Review 5.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

6.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

Review 7.  The roles of CD73 in cancer.

Authors:  Zhao-wei Gao; Ke Dong; Hui-zhong Zhang
Journal:  Biomed Res Int       Date:  2014-07-14       Impact factor: 3.411

8.  Interactions between Cisplatin and Quercetin at Physiological and Hyperthermic Conditions on Cancer Cells In Vitro and In Vivo.

Authors:  Nada Oršolić; Dyana Odeh; Maja Jazvinšćak Jembrek; Jelena Knežević; Darko Kučan
Journal:  Molecules       Date:  2020-07-17       Impact factor: 4.411

9.  Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

Authors:  R Zamora-Ros; C Sacerdote; F Ricceri; E Weiderpass; N Roswall; G Buckland; D E St-Jules; K Overvad; C Kyrø; G Fagherazzi; M Kvaskoff; G Severi; J Chang-Claude; R Kaaks; U Nöthlings; A Trichopoulou; A Naska; D Trichopoulos; D Palli; S Grioni; A Mattiello; R Tumino; I T Gram; D Engeset; J M Huerta; E Molina-Montes; M Argüelles; P Amiano; E Ardanaz; U Ericson; B Lindkvist; L M Nilsson; L A Kiemeney; M Ros; H B Bueno-de-Mesquita; P H M Peeters; K-T Khaw; N J Wareham; V Knaze; I Romieu; A Scalbert; P Brennan; P Wark; P Vineis; E Riboli; C A González
Journal:  Br J Cancer       Date:  2014-08-14       Impact factor: 7.640

10.  A novel synthetic derivative of quercetin, 8-trifluoromethyl-3,5,7,3',4'-O-pentamethyl-quercetin, inhibits bladder cancer growth by targeting the AMPK/mTOR signaling pathway.

Authors:  Ting Tao; Caimei He; Jun Deng; Yanjun Huang; Qiongli Su; Mei Peng; Meiling Yi; Kwame Oteng Darko; Hui Zou; Xiaoping Yang
Journal:  Oncotarget       Date:  2017-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.